CDK

ADC Related

ADC Antibody ADC Cytotoxin ADC Linker ADCs Drug-Linker Conjugates for ADC
Angiogenesis

5-alpha Reductase ALK Bcr-Abl BTK EGFR FAK FLT3 HER-2 HIF Src Syk VDA VEGFR
Anti-infection

Antibiotic Arenavirus Bacterial CMV EBV Enterovirus Filovirus Fungal Gli HBV HCV HCV Protease HIV HSV Influenza Virus Parasite RABV Reverse Transcriptase RSV SARS-CoV TMV Virus Protease
Apoptosis

Apoptosis ASK Bcl-2 Caspase c-Myc c-RET Cytohesin DAPK Ferroptosis FKBP IAP Mdm2 p53 PD-1 PD-L1 PERK PKD Ras RIP kinase ROS Survivin Thymidylate Synthase TNF Receptor TNFa TRADD
Autophagy

Autophagy LRRK2 Mitophagy OGA ULK
Cell Cycle

Antifolate APC Aurora Kinase BMI-1 CDK Chk c-Myc Eukaryotic Initiation Factor G-quadruplex HDAC HSP Kinesin LIMK Mad2 Microtubule(Tubulin) Mps1 Nucleoside Antimetabolite/Analog Nur77 p21 PAK PERK PFKFB PLK PPAR Ras Rho ROCK SRPK TOPK Topoisomerase Wee1
Cytoskeletal Signaling

Arp2 3 Complex Bcr-Abl Cardiac Myosin Dynamin Gap Junction Protein HSP Integrin Kinesin Microtubule Associated MLCK Myosin PAK TACC3 Wntbeta-catenin
DNA Damage

ATM(ATR) CRISPR(Cas9) DNA alkylator DNA Stain DNA(RNA) Synthesis GAK HDAC HSP Nucleoside Antimetabolite(Analog) OGG1 p97 PARG PARP RAD51 RNR Sirtuin SMN Telomerase Topoisomerase
Endocrinology & Hormones

5-alpha Reductase ACE Adrenergic Receptor Androgen Receptor Aromatase Estrogenprogestogen Receptor Glucocorticoid Receptor GPR Mineralocorticoid Receptor RAAS THR TSH Receptor
Epigenetics

AMPK Aurora Kinase DNA Methyltransferase Epigenetic Reader Domain EZH1 2 HDAC HIF Histone Acetyltransferase Histone Demethylase Histone Methyltransferase JAK MAT MicroRNA MLL Pim PKC Protein Arginine Deiminase Sirtuin Small Interfering RNA (siRNA) SMYD

+MORE

CDK

CDK related products

Cat No.	Product Name	CAS No.	Product Description
V52146	(E/Z)-BIO-acetoxime (GSK-3 Inhibitor X)	740841-15-0	(E/Z)-BIO-acetoxime (GSK-3 Inhibitor X) is a potent and specific GSK-3α/β inhibitor (antagonist) with IC50 of 10 nM.
V3635	(rel)-MC180295	2237942-08-2	(rel)-MC180295 is a novel, potent and selective CDK9-Cyclin T1 inhibitor with an IC50 of 5 nM and with broad anti-cancer activity in vitro.
V90764	(S)-(-)-O-Demethylbuchenavianine	91147-18-1	(S)-(-)-O-Demethylbuchenavianine (Compound (S)-(−)-1) is a flavonoid alkaloid.
V113250	(S)-JWZ-5-13		(S)-JWZ-5-13 (compound 17-Neg) is a PROTAC CDK7 degrader and a negative control compound for JWZ-5-13.
V122599	1,1-Dimethylethyl 4-(4-amino-3-pyridinyl)-1-piperazinecarboxylate	1023594-50-4	1,1-Dimethylethyl 4-(4-amino-3-pyridinyl)-1-piperazinecarboxylate is an impurity of palbociclib.
V122600	1,1-Dimethylethyl 4-(5-amino-3-pyridinyl)-1-piperazinecarboxylate	1245914-05-9	1,1-Dimethylethyl 4-(5-amino-3-pyridinyl)-1-piperazinecarboxylate is an impurity of palbociclib.
V1559	R547 (Ro 4584820)	741713-40-6	R547 (R-547;Ro4584820;R 547;Ro-4584820)is a potent, selective and ATP-competitive inhibitor of CDK1/2/4 with potential antitumor activity.
V75987	Anticancer agent 30	2907774-88-1	anti-cancer compound 30 (compound 6f-Z) is a 3-arylidene-2-oxindole analogue, a selective CDK2 inhibitor (antagonist) with potent anti-cancer effect.
V128974	Anticancer agent 300	1310059-06-3	Anticancer agent 300 is a CCND1, CDK4, CDK6 and CCNE1 regulator with anti-proliferation, cell cycle regulation, senescence induction and apoptosis induction activities.
V2745	ARS-853	1629268-00-3	ARS-853 is a novel, potent, selective, and covalent inhibitor of KRAS(G12C) with IC50 of 2.5 μM.
V11793	AT-7519 diHCl	902135-91-5	AT-7519 diHCl is a novel and potent multi-CDK (cyclin-dependent kinase) inhibitor for Cdk1/cyclin B, Cdk2/Cyclin A, Cdk3/Cyclin E, Cdk4/Cyclin D1, Cdk5/p35, and Cdk6/Cyclin D3 with IC50s of 210, 47, 100, 13, 170, and<10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.
V1537	AT7519	844442-38-2	AT7519 (AT-7519; AT 7519) is an orally bioavailable and potent inhibitor of multiple CDKs (cyclin-dependent kinases) with potential antitumor activity.
V7882	Atuveciclib (BAY-1143572)	2923012-24-0	Atuveciclib (BAY-1143572) is a potent, orally bioactive and selective PTEFb/CDK9 inhibitor.
V129661	Aurora-A ligand 1	2541626-73-5	Aurora-A ligand 1 is a high-affinity, high-specificity Aurora-A inhibitor with a dissociation constant (Kd) of 0.85 nM.
V4060	AZD4573	2057509-72-3	AZD4573 (AZD-4573) is a novel, potent and short acting inhibitor ofserine/threonine CDK9(cyclin-dependent kinase 9, IC50<0.004 μM) with potential anticancer activities.
V1555	AZD5438	602306-29-6	AZD5438 (AZD-5438;AZD 5438) is a novel, potent and selective small molecule inhibitor of cyclin-dependent kinase (CDK) 1, 2 and 9 with potential antineoplastic activity.
V1554	BMS-265246	582315-72-8	BMS-265246 (BMS265246;BMS 265246) is a novel, potent and selective CDK1/2 (Cyclin-dependent kinases) inhibitor with potential antitumor activity.
V130626	BRD4/AKT-IN-1	3087270-50-3	BRD4/AKT-IN-1 is a BRD4/AKT inhibitor with an IC50 of 66.12 nM against BRD4 and 143.81 nM against AKT1.
V80116	CAF-382		CAF-382 (compound B1) is an SNS-032 analogue and a CDKL5 and pan-CDK inhibitor (antagonist) with weak GSK3α/β affinity (>1.8 μM) and inhibitory activity.
V0062	PHA 767491	845714-00-3	PHA-767491 (formerly also called CAY10572) is a novel and potent ATP-competitive dual inhibitor of Cdc7/CDK9 with IC50 of 10 nM and 34 nM in cell-free assays, respectively.